Argonaut Technologies Initiates West Coast Seminar Series; Agenda Examines Technology for Accelerating Drug Discovery and Development.Business Editors/High Tech & Medical Writers FOSTER CITY, Calif.--(BUSINESS WIRE)--June 11, 2002 Argonaut Technologies, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AGNT AGNT Association for Global New Thought AGNT Agent Table ) announced today its educational West Coast Seminar Series for drug discovery and process R&D chemists. The series opens Tuesday, June 18, 2002 in La Jolla La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , California. A second seminar will take place on Thursday, June 20, 2002 in South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. . Argonaut's scientific staff of chemists will conduct the seminars to provide pharmaceutical chemists with the latest information on technologies that overcome bottlenecks in chemical synthesis, analysis, purification, and production. "The West Coast Seminar Series program recognizes the fact that biotech and biopharmaceutical organizations in this region derive their value from scientific innovation and technology leadership," said Julia Horak, vice president of marketing at Argonaut. "The seminars will provide information that scientists engaged in research activities, from drug discovery to process development, can apply to maintain that leadership position and capitalize on their own organizations' unique areas of knowledge." For drug discovery chemists, the seminar series will describe strategies for automation, compound purification using solid phase extraction Solid-phase extraction (SPE) is a separation process that is used to extract compounds (called analytes) from a mixture of impurities. Analytical laboratories use solid phase extraction to concentrate and purify samples for analysis. , transferring separation processes from thin-layer chromatography thin-layer chromatography (TLC) Type of chromatography using as the stationary phase a thin layer (0.01 inch [0.25 mm]) of a special finely ground matrix (silica gel, alumina, or similar material) coated on a glass plate or incorporated in a plastic film. to flash chromatography and streamlining the purification of solution-phase reaction products. For process R&D chemists, Argonaut will present practical information on parallel sample experimentation, analytical instrument integration, automation and rapid scale-up. Registration is free, with space for attendees assigned on a first-come, first-served basis. Argonaut invites interested chemists and R&D managers to register by calling (877) 655-4200 or by visiting the company's seminar series web page, www.argotech.com/seminars. About Argonaut Argonaut Technologies, Inc. is a leading provider of instruments, chemistry consumables, software, and services designed to accelerate and improve chemical development processes. The company's products are designed to enable chemists to increase productivity, reduce operating costs through automation and process simplification, achieve faster time-to-market, and explore the increasing number of targets and chemical compounds available for drug and chemical development. Argonaut's products are used in more than 1,000 pharmaceutical, chemical, and academic laboratories worldwide. For more information, visit www.argotech.com. Forward-Looking Statements Statements included in this press release that are not historical in nature may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Examples of such forward-looking statements include, without limitation, statements regarding the ability of our products to enhance and accelerate drug and chemical development. Any such forward-looking statements involve risks and uncertainties including the risk that events named in this press release may not proceed as planned and reflect Argonaut's intentions as of the date of this release. These and other risk factors are discussed in Argonaut's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 2001 filed on April 1, 2002, in its most recent quarterly report on Form 10-Q Form 10-Q See 10-Q. for the quarter ended March 31, 2002 filed on May 15, 2002, and its other filings with the Securities and Exchange Commission. Argonaut disclaims any intent or obligation to update these forward-looking statements. The Company claims the protection of the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion